Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac, the company's innovative vaccine against strangles in horses. The application seeks to extend the stated duration of immunity to 12 months, supported by data demonstrating that correlates of protection persist for 12 months following completion of the primary vaccination course.
Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses worldwide. Strangvac, a unique recombinant protein vaccine, has been successfully used for protection against disease. Based on the data package submitted with the original marketing authorization application, the product information specifies a duration of immunity of only two months.
By demonstrating an immune response with antibody titers that are protective in challenge studies, a correlate of protection has been established. Following the immune response in vaccinated horses over time shows that these protective antibody levels are sustained for 12 months. Thus, Strangvac has a 12-month duration of immunity and protection. This study was recently published in a peer-reviewed journal (Paillot R & al, Vaccines 2026, 14, 533) that now constitutes the basis for the variation.
"If approved, a 12-month duration of immunity would make vaccination significantly more convenient, as revaccination against strangles could be coordinated with routine influenza vaccination. This would be a major advantage for horse owners," says Carl-Johan Dalsgaard, CEO of Intervacc.
For more information please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 (0)8 120 10 600
E-mail: carl-johan.dalsgaard@intervacc.se
The information was submitted for publication, through the agency of the contact person set out above on July 30, 2026 at 08.30 CET.
About Strangvac
Strangvac is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.
About Intervacc
Intervacc AB is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, visit intervacc.se
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10